E-Prescribing Market Analysis, Share, Growth and Forecast Report 2024
by Vijay K. Web MarketingE-Prescribing system facilities the practitioner to generate a new prescription electronically whenever treatment error occurs during healthcare operations. E-Prescribing system offers extensive range of applications. It provides comprehensive form of medical data, ensures all security checks and patents identification. It offers complete privacy to the disease information and patient’s identification with present and historical data.
Browse report sample at: https://www.psmarketresearch.com/market-analysis/e-prescribing-market/report-sample
The global e-prescription market is predominantly driven by the increasing adoption of e-prescription in healthcare systems. It offers cost benefits over the conventional prescription market in longer run while ensuring quality healthcare services to patients at minimized treatments and adverse drug errors. Moreover the various government initiatives such as American Recovery and Reinvestment Act (ARRA) in 2009 for the advancement of the Healthcare IT, and HITECH Act is driving the demand of e-Prescribing systems in North America.
High initial cost of the electronics prescription systems is one of the major challenge for the growth of the market especially in the cost conscious developing countries of Asia Pacific region. Moreover the lack of interest towards the technology, by the physician especially in developing countries is also restraining the growth of this market.
Explore full report at: https://www.psmarketresearch.com/market-analysis/e-prescribing-market
Major Competitors: The global e-prescription market is dominated by Bioclinica, Inc., Bizmatics Inc., CRF Health, DATARAK International, Inc., eResearch Technology, Inc., Some of the top competitors in the global clinical trial management system market are e-MDs, Inc., iMedX, Inc., Practice Fusion, Inc., SureScripts-RxHub, LLC, eClinicalWorks, LLC, and Quality System, Inc.
Sponsor Ads
Created on Apr 26th 2019 04:22. Viewed 278 times.
Comments
No comment, be the first to comment.